Local Tech Wire

DURHAM, N.C. – The move of Trimeris from its former headquarters in Morrisville to Durham cost the biopharmaceutical firm $496,000.

The disclosure came Thursday as Trimeris (Nasdaq: TRMS) reported its quarterly earnings.

Trimeris, which developed the AIDS drug Fuzeon, has been scaling back operations as sales of Fuzeon have faltered and the firm made decisions not to pursue other drug development while scaling back operations.

Fuzon is sold in partnership with Roche,

For the quarter, Trimeris reported a profit of $1.3 million, or 6 cents per share. Royalties from Fuzeon dropped to $1.6 million for the most recent quarter compared to $2.1 million a year ago.

Overall Fuzeon sales dropped 25 percent.

For more information,

Get the latest news alerts: at Twitter.